TY - JOUR

T1 - PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

AU - Ghaneh, Paula

AU - Hanson, Robert

AU - Titman, Andrew

AU - Lancaster, Gill

AU - Plumpton, Catrin

AU - Lloyd-Williams, Huw

AU - Yeo, Seow Tien

AU - Edwards, Rhiannon

AU - Johnson, Colin

AU - Abu Hilal, Mohammed

AU - Higginson, Antony

AU - Armstrong, Tom

AU - Smith, Andrew

AU - Scarsbrook, Andrew

AU - McKay, Colin

AU - Carter, Ross

AU - Sutcliffe, Robert

AU - Bramhall, Simon

AU - Kocher, Hemant

AU - Cunningham, David

AU - Pereira, Stephen

AU - Davidson, Brian

AU - Chang, David

AU - Khan, Saboor

AU - Zealley, Ian

AU - Sarker, Debashis

AU - Al Sarireh, Bilal

AU - Charnley, Richard

AU - Lobo, Dileep

AU - Nicolson, Marianne

AU - Halloran, Christopher

AU - Raraty, Michael

AU - Sutton, Robert

AU - Vinjamuri, Sobhan

AU - Evans, Jonathan

AU - Campbell, Fiona

AU - Deeks, Jon

AU - Sanghera, Bal

AU - Wong, Wai-Lup

AU - Neoptolemos, John

N1 - © Queen’s Printer and Controller of HMSO 2018. This work was produced by Ghaneh et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. The report was signed off following editorial review on 23rd February 2016. It then completed the production process on 25 October 2016 before being held until publication on 6th February 2018.

PY - 2018/2/6

Y1 - 2018/2/6

N2 - Overall survival for patients with pancreatic cancer remains poor. Challenges in the care of patients with pancreatic cancer include late presentation and difficulties in early diagnosis. Standard diagnosis of patients with pancreatic cancer consists of a computed tomography (CT) scan, a magnetic resonance imaging (MRI) scan and camera tests. Additional imaging tests may be able to identify pancreatic cancer and the stage of disease more effectively. This would mean that patients would receive the most appropriate treatment at the right time. Positron emission tomography (PET)/CT is a nuclear medicine scan that gives a functional image of the body along with the CT scan. This study used PET/CT in patients with suspected pancreatic cancer as well as standard tests to see if the diagnosis and treatment of these patients could be improved. In total, 550 patients had PET/CT scans. The PET/CT added significantly to the accuracy of standard tests, improving the diagnosis of pancreatic cancer. PET/CT influenced the management of 45% of patients. PET/CT was able to correctly stage the extent of the tumours in a greater number of patients than standard diagnostic tests. This meant that the addition of PET/CT changed the management of these patients to more appropriate therapies. The biggest benefit was seen for those patients who were due to have surgery. We calculated that the use of PET/CT was likely to be good value for money for the NHS. This study suggests that PET/CT is likely to be beneficial in the diagnosis and management of patients with suspected pancreatic cancer.

AB - Overall survival for patients with pancreatic cancer remains poor. Challenges in the care of patients with pancreatic cancer include late presentation and difficulties in early diagnosis. Standard diagnosis of patients with pancreatic cancer consists of a computed tomography (CT) scan, a magnetic resonance imaging (MRI) scan and camera tests. Additional imaging tests may be able to identify pancreatic cancer and the stage of disease more effectively. This would mean that patients would receive the most appropriate treatment at the right time. Positron emission tomography (PET)/CT is a nuclear medicine scan that gives a functional image of the body along with the CT scan. This study used PET/CT in patients with suspected pancreatic cancer as well as standard tests to see if the diagnosis and treatment of these patients could be improved. In total, 550 patients had PET/CT scans. The PET/CT added significantly to the accuracy of standard tests, improving the diagnosis of pancreatic cancer. PET/CT influenced the management of 45% of patients. PET/CT was able to correctly stage the extent of the tumours in a greater number of patients than standard diagnostic tests. This meant that the addition of PET/CT changed the management of these patients to more appropriate therapies. The biggest benefit was seen for those patients who were due to have surgery. We calculated that the use of PET/CT was likely to be good value for money for the NHS. This study suggests that PET/CT is likely to be beneficial in the diagnosis and management of patients with suspected pancreatic cancer.

U2 - 10.3310/hta22070

DO - 10.3310/hta22070

M3 - Article

VL - 22

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 7

ER -